Glen Eagle Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $193K | Sell |
3,503
-81
| -2% | -$4.39K | 0.03% | 266 |
|
|
2025
Q4 | $176K | Buy |
3,584
+721
| +25% | +$33.6K | 0.02% | 275 |
|
|
2025
Q3 | $124K | Sell |
2,863
-64
| -2% | -$2.5K | 0.02% | 307 |
|
|
2025
Q2 | $112K | Sell |
2,927
-150
| -5% | -$5.73K | 0.02% | 301 |
|
|
2025
Q1 | $119K | Buy |
3,077
+436
| +17% | +$16K | 0.02% | 291 |
|
|
2024
Q4 | $89.3K | Buy |
2,641
+42
| +2% | +$1.51K | 0.01% | 325 |
|
|
2024
Q3 | $106K | Sell |
2,599
-10
| -0.4% | -$409 | 0.02% | 304 |
|
|
2024
Q2 | $100K | Buy |
2,609
+1,022
| +64% | +$43K | 0.02% | 301 |
|
|
2024
Q1 | $68K | Buy |
1,587
+81
| +5% | +$3.34K | 0.01% | 363 |
|
|
2023
Q4 | $55.8K | Buy |
1,506
+1
| +0.1% | +$36 | 0.01% | 371 |
|
|
2023
Q3 | $54.6K | Buy |
1,505
+1
| +0.1% | +$35 | 0.01% | 362 |
|
|
2023
Q2 | $53.6K | Buy |
1,504
+1
| +0.1% | +$36 | 0.01% | 367 |
|
|
2023
Q1 | $53.5K | Buy |
1,503
+65
| +5% | +$2.27K | 0.01% | 357 |
|
|
2022
Q4 | $50.5K | Buy |
1,438
+43
| +3% | +$1.43K | 0.01% | 357 |
|
|
2022
Q3 | $41.1K | Sell |
1,395
-239
| -15% | -$9.06K | 0.01% | 375 |
|
|
2022
Q2 | $88.9K | Sell |
1,634
-8
| -0.5% | -$442 | 0.02% | 292 |
|
|
2022
Q1 | $89.4K | Hold |
1,642
| – | – | 0.02% | 294 |
|
|
2021
Q4 | $90.5K | Sell |
1,642
-88
| -5% | -$4.58K | 0.02% | 289 |
|
|
2021
Q3 | $82.6K | Buy |
1,730
+2
| +0.1% | +$100 | 0.02% | 299 |
|
|
2021
Q2 | $86K | Buy |
1,728
+2
| +0.1% | +$96 | 0.03% | 290 |
|
|
2021
Q1 | $77K | Buy |
1,726
+1
| +0.1% | +$45 | 0.03% | 282 |
|
|
2020
Q4 | $79.3K | Sell |
1,725
-98
| -5% | -$4.5K | 0.03% | 263 |
|
|
2020
Q3 | $85.8K | Buy |
1,823
+1
| +0.1% | +$50 | 0.04% | 236 |
|
|
2020
Q2 | $92.9K | Buy |
1,822
+19
| +1% | +$975 | 0.05% | 215 |
|
|
2020
Q1 | $85.4K | Buy |
1,803
+194
| +12% | +$10.3K | 0.06% | 207 |
|
|
2019
Q4 | $94.5K | Buy |
1,609
+1
| +0.1% | +$56 | 0.05% | 232 |
|
|
2019
Q3 | $85.8K | Sell |
1,608
-78
| -5% | -$4.01K | 0.06% | 213 |
|
|
2019
Q2 | $84.4K | Hold |
1,686
| – | – | 0.06% | 215 |
|
|
2019
Q1 | $88K | Buy |
1,686
+2
| +0.1% | +$100 | 0.06% | 207 |
|
|
2018
Q4 | $80.4K | Buy |
1,684
+2
| +0.1% | +$98 | 0.07% | 202 |
|
|
2018
Q3 | $84.5K | Hold |
1,682
| – | – | 0.06% | 219 |
|
|
2018
Q2 | $84.7K | Buy |
1,682
+2
| +0.1% | +$101 | 0.07% | 211 |
|
|
2018
Q1 | $82K | Buy |
1,680
+182
| +12% | +$8.48K | 0.07% | 207 |
|
|
2017
Q4 | $66.5K | Hold |
1,498
| – | – | 0.06% | 225 |
|
|
2017
Q3 | $76K | Buy |
1,498
+1,018
| +212% | +$51.6K | 0.07% | 208 |
|
|
2017
Q2 | $25.9K | Hold |
480
| – | – | 0.02% | 280 |
|
|
2017
Q1 | $25.3K | Hold |
480
| – | – | 0.02% | 265 |
|
|
2016
Q4 | $23.1K | Buy |
+480
| New | +$23.7K | 0.02% | 266 |
|
Other funds holding GSK
JEST
Glen Eagle Advisors's GSK Position: Q1 2026 in Review
Glen Eagle Advisors reduced its GSK (GSK) stake by 2.3% in Q1 2026, selling an estimated $4.39K and leaving 3,503 shares worth $193K. The position accounts for 0.03% of the portfolio, ranked #266.
Glen Eagle Advisors first reported a position in GSK in Q4 2016 and has held it in 38 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Glen Eagle Advisors held 3,503 shares of GSK worth $193K as of Q1 2026.
- Glen Eagle Advisors sold 81 GSK shares in Q1 2026, an estimated $4.39K.
- GSK made up 0.03% of Glen Eagle Advisors's portfolio in Q1 2026, its #266 holding.
- Glen Eagle Advisors first reported a position in GSK in Q4 2016 and has held it in 38 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.